Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy
Oxidative stress has been implicated in the pathogenesis of various disorders, including diabetic retinopathy (DR). Oxidative stress-responsive apoptosis-inducing protein (ORAIP; a tyrosine-sulfated secreted form of eukaryotic translation initiation factor 5A [eIF5A]) is a recently discovered pro-apoptotic ligand that is secreted from cells in response to oxidative stress and induces apoptosis in an autocrine fashion. This study aimed to determine if ORAIP plays a role in DR.
To investigate the role of ORAIP in DR, we analyzed the levels of ORAIP in the vitreous body and their relationship with the extent of proliferative diabetic retinopathy (PDR). Enzyme-linked immunosorbent assay was used to quantify the levels of ORAIP, vascular endothelial growth factor (VEGF), C–C motif chemokine ligand 2 (CCL2), interleukin-6 (IL-6), and IL-8 in the vitreous body of 40 eyes from 28 patients with PDR and 11 patients with non-PDR (NPDR). We also analyzed the expression of ORAIP in insoluble proliferative tissues from vitreous body samples by immunofluorescent staining.
The vitreous body concentration of ORAIP was significantly (P = 0.0433) higher in the PDR group (52.26 ± 8.68 [mean ± SE] ng/mL, n = 29) than in the NPDR group (28.21 ± 7.30 ng/mL, n = 11). However, there were no significant correlations between the concentration of ORAIP and those of VEGF, IL-6, CCL2, or IL-8. ORAIP expression was observed in the insoluble proliferative tissues in vitreous body samples of most patients in the PDR group, whereas almost no expression of ORAIP was observed in patients in the NPDR group.
Our findings strongly suggest that ORAIP plays a role in oxidative stress-induced retinal injury and may be a sensitive diagnostic marker and a promising therapeutic target for oxidative stress-induced cytotoxicity.
KeywordsChemokines Diabetic retinopathy Oxidative stress-responsive apoptosis inducing protein Proliferative diabetic retinopathy Vascular endothelial growth factor Vitreous body
Editorial support in the form of medical writing was provided by Editage (www.editage.com), a division of Cactus Communications Pvt., Ltd.
This work was supported by a grant from Takeda Research Support and Novartis Pharma Research Grants and by research support from Alcon Pharma, Senju Pharmaceutical Co. Ltd. and Bayer Pharmaceutical Co., Ltd.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and was approved by the Ethics Committee of Tokyo Women’s Medical University.
Informed written consent was obtained from all patients before ophthalmologic examination.
- 4.Nawaz MI, Van Raemdonck K, Mohammad G, Kangave D, Van Damme J, Abu El-Asrar AM, Struyf S (2013) Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res 109:67–76. https://doi.org/10.1016/j.exer.2013.01.008 CrossRefGoogle Scholar
- 7.Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, Park BJ, Korean Meta-Analysis Study Group (2013) Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. Br Med J 346:f10. https://doi.org/10.1136/bmj.f10 CrossRefGoogle Scholar
- 10.Yao T, Fujimura T, Murayama K, Okumura K, Seko Y (2017) Oxidative stress-responsive apoptosis inducing protein (ORAIP) plays a critical role in high glucose-induced apoptosis in rat cardiac myocytes and murine pancreatic β-cells. Cells 6:35. https://doi.org/10.3390/cells6040035 CrossRefGoogle Scholar
- 14.Tanaka K, Yao T, Sato K, Okumura K, Seko Y (2017) Oxidative stress-responsive apoptosis inducing protein (ORAIP) plays a critical role in the cardiac injury in patients with heart failure. Ann Pharmacol Pharm 2:1100Google Scholar
- 16.Shanab AY, Nakazawa T, Ryu M, Tanaka Y, Himori N, Taguchi K, Yasuda M, Watanabe R, Takano J, Saido T, Minegishi N (2012) Metabolic stress response implicated in diabetic retinopathy: the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiol Dis 48:556–567. https://doi.org/10.1016/j.nbd.2012.07.025 CrossRefGoogle Scholar
- 18.Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119:789–801. https://doi.org/10.1016/j.ophtha.2011.12.039 CrossRefGoogle Scholar
- 20.Mandal LK, Choudhuri S, Dutta D, Mitra B, Kundu S, Chowdhury IH, Sen A, Chatterjee M, Bhattacharya B (2013) Oxidative stress-associated neuroretinal dysfunction and nitrosative stress in diabetic retinopathy. Can J Diabetes 37:401–407. https://doi.org/10.1016/j.jcjd.2013.05.004 CrossRefGoogle Scholar
- 22.Jiang Y, Sang Y, Qiu Q (2017) MicroRNA-383 mediates high glucose-induced oxidative stress and apoptosis in retinal pigment epithelial cells by repressing peroxiredoxin 3. Am J TrMnsl Res 9:2374–2383Google Scholar
- 24.Jiao C, Dean Eliott MD, Spee C, He S, Wang K, Mullins RF, Hinton DR, Sohn EH (2017) Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: results of a prospective trial report no. 2. Retina 39:265–273. https://doi.org/10.1097/IAE.0000000000001952 CrossRefGoogle Scholar
- 25.Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Brigell M (2016) Enhanced benefit in diabetic macular edema from akb-9778 tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123:1722–1730. https://doi.org/10.1016/j.ophtha.2016.04.025 CrossRefGoogle Scholar
- 26.Regula JT, von Leithner PL, Foxton R, Barathi VA, Cheung CM, Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265–1288. https://doi.org/10.15252/emmm.201505889 CrossRefGoogle Scholar